

## Basic science: (February 2008)

1. Arnes JB, Collett K, Akslen LA. Lesson of the month – independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. *Histopathology* 2008; **52**: 370–380.
2. Averous J, Fonseca BD, Proud CG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. *Oncogene* 2008; **27**: 1106–1113.
3. Bergarnaschi A, Tagliabue E, Sorlie T, Naurne B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Menard S, Borresen-Dale AL. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. *J Pathol* 2008; **214**: 357–367.
4. Blank EW, Wong PY, Lakshmanaswamy R, Guzman R, Nandi S. Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. *Proc Natl Acad Sci USA* 2008; **105**: 3527–3532.
5. Fritah A, Saucier C, De Wever O, Bracke M, Bieche I, Lidereau R, Gerspach C, Drouot S, Redeuilh G, Sabbah M. Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. *Mol Cell Biol* 2008; **28**: 1114–1123.
6. Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Bersch AJ, Stampfer MJ, Baron JA, Egan KM, Willett WC. Physical activity and survival after diagnosis of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 379–386.
7. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt ANJ, Crook T, Lord CJ, Ashworth A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. *Cancer Cell* 2008; **13**: 91–104.
8. Kouros-Mehr H, Bechis SK, Storch EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. *Cancer Cell* 2008; **13**: 141–152.
9. Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. *Oncogene* 2008; **27**: 1472–1477.
10. Levy N, Tatomer D, Herber CB, Zhao XY, Tang H, Sargeant T, Ball LJ, Summers J, Speed TP, Leitman DC. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. *Mol Endocrinol* 2008; **22**: 287–303.
11. Liu HL, Liu Y, Zhang JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. *Mol Cancer Therap* 2008; **7**: 263–270.
12. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS. BRCA1 regulates human mammary stem/progenitor cell fate. *Proc Natl Acad Sci USA* 2008; **105**: 1680–1685.
13. Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S, Licht JD, Ishii S. ATF-2 controls transcription of Maspin and GADD45  $\alpha$  genes independently from p53 to suppress mammary tumors. *Oncogene* 2008; **27**: 1045–1054.
14. Meijer D, Jansen M, Look M, Ruigrok-Ritstier K, Staveren I, Sieuwerts A, Agthoven T, Foekens J, Dorssers L, Berns E. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. *Breast Cancer Res Treat* 2008; 10.1007/s10549-008-9934-3.
15. Parker BS, Ciocca DR, Bidwell BN, Gago FE, Fanelli MA, George J, Slavin JL, Moller A, Steel R, Pouliot N, Eckhardt BL, Henderson MA, Anderson RL. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. *J Pathol* 2008; **214**: 337–346.

16. Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. *Cancer Res* 2008; **68**: 998–1002.
17. Rahman M, Davis S, Pumphrey J, Bao J, Nau M, Meltzer P, Lipkowitz S. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. *Breast Cancer Res Treat* 2008; 10.1007/s10549-008-9924-5.
18. Reineke EL, Lam M, Liu O, Liu Y, Stanya KJ, Chang KS, Means AR, Kao HY. Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. *Mol Cell Biol* 2008; **28**: 997–1006.
19. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* 2008; **451**: 1116–1120.
20. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial–mesenchymal transition in breast cancer relates to the basal-like phenotype. *Cancer Res* 2008; **68**: 989–997.
21. Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. *Oncogene* 2008; **27**: 1095–1105.
22. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells – evidence of a BRCA1 and p300 exchange. *J Biol Chem* 2008; **283**: 3433–3444.
23. Thangasamy A, Rogge J, Ammanamanchi S. Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells. *J Biol Chem* 2008; **283**: 5335–5343.
24. Travis RC, Allen NE, Appleby PN, Spencer EA, Roddam AW, Key TJ. A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. *Int J Cancer* 2008; **122**: 705–710.
25. Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 365–373.
26. Wendt MK, Cooper AN, Dwinell MB. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. *Oncogene* 2008; **27**: 1461–1471.
27. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA. A genome-wide study of the repressive effects of estrogen receptor  $\beta$  on estrogen receptor  $\alpha$  signaling in breast cancer cells. *Oncogene* 2008; **27**: 1019–1032.

Prepared by  
R Sutherland  
Cancer Research Program  
Garvan Institute of Medical Research  
Darlinghurst, NSW, Australia